The Polio Transition1
Monitoring and Evaluation (M&E) Framework was designed to monitor progress towards achieving the strategic and operational outcomes of the post-2023 Strategic Action Plan on Polio Transition (2018– 2023), as outlined in the Global Vision to use polio investments to build st...rong, resilient and equitable health systems (the Global Vision), and regional strategic plans for the WHO African, Eastern Mediterranean and SouthEast Asia Regions. It aims to support an efficient and effective polio transition process through both process and outcome-based monitoring. The M&E Framework promotes accountability and strives for a harmonized approach to monitoring and evaluating the polio transition at the country, regional and global levels
more
Challenges in achieving the MDG for maternal mortality. In-depth analysis of the EDHS 2000-2011
Standard Treatment Guideline
ARC resource pack - Study material
In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce and productivity). In this study, it is estimated that NCDs cost Ethiop...ia at least 31.3 billion birr (US$ 1.1 billion) per year, equivalent to 1.8% of the gross domestic product (GDP). Less than 15% of the costs are for health care.
more
Tokar A, et al. Sex Transm Infect 2019;95:193–200. doi:10.1136/sextrans-2018-053684
May 2018
HIV i-Base
ISSN 1475-2077 www.i-Base.info
Watch for out-of-date information
First questions
You and your doctor Resistance and adherence Treatment choices
The main objective of this guidance is to provide scientific advice on public health principles and considerations for infection and prevention control of COVID-19 in migrant and refugee reception and detention centres in the European Union and European Economic Area (EU/EEA) and the United Kingdom ...(UK).
more
Working Paper 589 July 2021T
MMWR Morbidity and Mortality Weekly Report December 19, 2014 / 63(50);1205-1206
March 28, 2017https://doi.org/10.1371/journal.pmed.1002274
PLoS Med 14(3): e1002274. https://doi.org/10.1371/journal.pmed.1002274
DRUGS REGULATORY UNIT | NOVEMBER 2009 | SECOND EDITION